Recent Quotes (30 days)

You have no recent quotes
chg | %

Kane Biotech Inc  

(Public, CVE:KNE)   Watch this stock  
Find more results for kne
0.0500
0.0000 (0.00%)
Delayed:   11:42AM EDT
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.05 - 0.05
52 week 0.03 - 0.12
Open 0.05
Vol / Avg. 304,400.00/101,226.00
Mkt cap 5.36M
P/E     -
Div/yield     -
EPS -0.02
Shares 107.02M
Beta 0.64
Inst. own     -

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -1834.71% -904.89%
Operating margin -1703.00% -906.91%
EBITD margin - -884.76%
Return on average assets -103.87% -65.67%
Return on average equity -187.24% -79.72%
CDP Score - -

Address

Suite 162, 196 Innovation Drive
WINNIPEG, MB R3T 2N2
Canada
+1-204-4531301 (Phone)
+1-204-4747552 (Fax)

Website links

Description

Kane Biotech Inc. (Kane) is a Canada-based company engaged in the development and commercialization of products that prevent and remove microbial biofilms. The Company�s technologies include DispersinB, Aledex, StrixNB and KBI Antibacterial Disinfectant (KBI). Kane�s technology for the wound care market is DispersinB. The Company has a number of DispersinB formulations in development, including formulations with antibiotics and the antibiofilm enzyme B-N-Acetylglucosaminidase. Kane has developed antibiofilm-antimicrobial formulations for both the veterinary and human markets. The Aledex is used in medical device coating market. The KBI contains antimicrobial-antibiofilm combination consists of Chlorhexidine (CHX) and Sodium Metaperiodate (SMP). The StrixNB is used for the oral care market.

Officers and directors

Philip Renaud Independent Chairman of the Board
Gordon Froehlich President, Chief Executive Officer, Director
Mark Matthewson Chief Financial Officer
Arvind K. Joshi M.D. Director
Mark H. Nawacki Director
Sarah Prichard Director